Adult variant of self-healing papular mucinosis in a patient treated with interferon α2a

Fernández, Daniel González; Allende, Blanca Vivanco; Oliva, Narciso Pérez

doi:10.4103/0378-6323.129421

Cited by 10 publications

(7 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no symptoms associated in four reported cases (Table 1). [33][34][35][36][37][38][39][40][41]…”

Section: Figurementioning

confidence: 99%

“…In both patients, mucin deposits within the dermal stroma were consistent with dark spaces between thin collagen fibers. In addition, spindle-shaped fibroblasts within the mucinous areaswith fusiform-to-dendritic structures -were observed to be thicker 36 Laura Atzori 2014, 37 Kołodziejczyk, Beata 2017, 38 Luo, D 2011, 39 Alvarez-Garrido 2014, 40 Gomez Sanchez, Maria Encarnacion 2016. 41 DPLM, discrete papular lichen myxedematosus; APPM, acral persistent papular mucinosis; SPM, self-healing papular mucinosis; CMI, cutaneous mucinosis of infancy; NLM, nodular lichen myxedematosus; ILC, intralesional corticosteroids; CNI, calcineurin inhibitor; DM, diabetes mellitus An Bras Dermatol.…”

Section: Histologymentioning

confidence: 99%

See 1 more Smart Citation

Lichen myxedematosus: a rare group of cutaneous mucinosis

Cardenas-Gonzalez

Herz‐Ruelas

Candiani

2019

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…There were no symptoms associated in four reported cases (Table 1). [33][34][35][36][37][38][39][40][41]…”

Section: Figurementioning

confidence: 99%

Section: Histologymentioning

confidence: 99%

Lichen myxedematosus: a rare group of cutaneous mucinosis

Cardenas-Gonzalez

Herz‐Ruelas

Candiani

2019

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Creatine phosphokinase levels and urinary myoglobin concentrations should be monitored during treatment because of the possibility of rhabdomyolysis 88 . In one case report, the onset and remission of SMX coincided with the administration of IFN‐α‐2a for the treatment of hepatitis C 89 . In another case, coma was precipitated after IFN‐α‐2b therapy 91 .…”

Section: Discussionmentioning

confidence: 99%

“…Retinoids (oral isotretinoin and acitretin) 86,87 have been shown to modulate the glycosaminoglycan synthesis and reduce the mucin production by fibroblasts in SMX, leading to clinical improvement. IFN has immunomodulatory and antiproliferative effects and may play a role in the treatment of SMX 88‐90 . Creatine phosphokinase levels and urinary myoglobin concentrations should be monitored during treatment because of the possibility of rhabdomyolysis 88 .…”

Section: Discussionmentioning

confidence: 99%

Scleromyxedema treatment: a systematic review and update

2020

View full text Add to dashboard Cite

Importance Scleromyxedema is a chronic disease with high morbidity and mortality and no definitive therapeutic guidelines. Objective To review all available data on the efficacy and the safety of the available treatments of scleromyxedema and suggest a possible therapeutic approach. Evidence Review We performed a systematic literature review in Pubmed/Medline, Embase, and Cochrane collaboration databases, searching for all articles since 1990 on the treatments of scleromyxedema, with no limits on participant age, gender, or nationality. Findings Ninety-seven studies were included in this systematic review, of which one prospective, two retrospective, 70 case reports/case series, and 24 letters/correspondence/ clinical image. Intravenous immunoglobulin (IVIG) was the most used first-line therapy based on its efficacy and its generally well-tolerated nature; most patients require continued treatment to remain in remission. Thalidomide and systemic glucocorticoids were mostly considered as second-line therapies and were given alone or in association with IVIG. Patients with severe or refractory disease were treated with autologous bone marrow transplantation, melphalan, or bortezomib with dexamethasone. Conclusions and Relevance Consideration of patient comorbidities, disease distribution, clinician experience, and treatment accessibility is mandatory in every therapeutic approach of scleromyxedema.

show abstract

“…Development of drug‐induced or toxic dermal mucinous deposits is an exceedingly unusual event, occasionally reported either as a localized phenomenon secondary to interferon injections 4 or anti‐tumor necrosis factor treatments; 5 or in a subset of distinctive disorders, including toxic oil syndrome or eosinophilia–myalgia syndrome 6 …”

Section: Discussionmentioning

confidence: 99%

Diffuse dermal mucinosis secondary to colony‐stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug‐induced diffuse cutaneous mucinosis

Olmos-Alpiste¹,

Segura²,

Tomás‐Velázquez³

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Colony‐stimulating factor 1 receptor (CSF1R) inhibitors represent a new class of immune‐modulatory drugs, mostly investigated in clinical trials in different malignant neoplasms. Four patients, diagnosed with recurrent or advanced malignant neoplasm and treated with a combination of anti‐programmed death ligand 1 and anti‐CSF1R monoclonal antibodies, developed an asymptomatic cutaneous eruption characterized by an ill‐defined pseudoedematous to waxy diffuse infiltration with a reticular cobblestone‐like pattern. Histopathological examination revealed diffuse mucin deposition involving the superficial and mid‐dermis with fragmented and scattered elastic fibers. The exact pathogenic mechanisms implicated in the development of mucin deposits in patients treated with CSF1R inhibitors remain to be elucidated. A reduced degradation and clearance of components of the extracellular matrix by macrophages secondary to CSF1 pathway inhibition may be hypothesized. Shredding and fragmentation of elastic fibers may be a result of the increased accumulation of mucopolysaccharides. This observation illustrates the new spectrum of skin‐related toxicities secondary to new targeting therapies. This may contribute to a better understanding of the underlying pathogenic mechanisms in skin diseases characterized by a persistent dermal glycosaminoglycan deposition.

show abstract

Adult variant of self-healing papular mucinosis in a patient treated with interferon α2a

Cited by 10 publications

References 4 publications

Lichen myxedematosus: a rare group of cutaneous mucinosis

Lichen myxedematosus: a rare group of cutaneous mucinosis

Scleromyxedema treatment: a systematic review and update

Diffuse dermal mucinosis secondary to colony‐stimulating factor 1 receptor monoclonal antibody treatment: A novel and peculiar drug‐induced diffuse cutaneous mucinosis

Contact Info

Product

Resources

About